Introduction
Statins, through reduction of plasma levels of low-density lipoprotein cholesterol (LDL-C), are widely used for the treatment of hyperlipidemia, and subsequently for the prevention of coronary heart disease. Rosuvastatin, a synthetic statin, is a stronger HMG-CoA reductase inhibitor, and more effective in lowering LDL-C than other statins such as atorvastatin and pravastatin (Jones et al., 2003) . However, there is considerable inter-individual variability in the efficacy and toxicity of rosuvastatin. Clinical trial data suggests that Asian-Americans may have higher plasma drug levels and be at greater risk for rosuvastatin-produced side effects than the general population (US Food ATP-binding cassette G2 protein (ABCG2, also known as breast cancer resistance protein) is a membrane efflux transporter which is expressed in various normal tissues such as the small intestine, colon, liver, and kidney, and plays a significant role in the disposition of various drugs (Gradhand and Kim, 2008; Hardwick et al., 2007) . Currently, more than 50 ABCG2 single nucleotide polymorphisms (SNPs) have been reported in various ethnic populations (Iida et al., 2002; Zamber et al., 2003; Kobayashi et al., 2005; Bäckström et al., 2003) . Previous studies have shown a significantly higher frequency of ABCG2 c.34G＞A (rs2231137) and c.421C＞A ). The ABCG2 c.421C>A polymorphism has been reported to markedly affect the pharmacokinetics, efficacy and toxicity of rosuvastatin (Zhang et al., 2006; Keskitalo et al., 2009a) . However, the importance of ABCG2 c.34G>A polymorphism in rosuvastatin disposition has not been studied in humans. Thus, the objective of this study is to determine the influence of ABCG2 c.34G>A SNP in rosuvastatin pharmacokinetics in healthy Chinese volunteers. As ABCG2 c.34G>A and c.421C>A variants are not in linkage disequilibrium (Kwan et al., 2011) and the reports of c.421CA heterozygotes on rosuvastatin disposition are inconsistent (Zhang et al., 2006; Keskitalo et al., 2009a) , the effect of ABCG2 34GA/421CA compound heterozygotes on rosuvastatin pharmacokinetics was also analyzed.
This article has not been copyedited and formatted. The final version may differ from this version. Genomic DNA from 800 healthy Chinese men was extracted from whole-blood samples using the QuickGene DNA whole blood kit (Kurabo, Osaka, Japan), and the DNA concentration was determined using a Nanodrop 2000. To determine the c.521T>C polymorphism of the SLCO1B1 gene, a 119 bp fragment was amplified by PCR using a specific pair of primers (Table 1) under the following conditions: one cycle pre-denaturation at 95°C for 5 min, 35 cycles of denaturation at 95° for 30 s, annealing at 53° for 30 s, and elongation at 72°C for 30 s, and one cycle of post-elongation at 72°C for 5 min. The ABCG2 c.34G>A and c.421C>A polymorphic regions were amplified by PCR using the primer pairs indicated in Table 1 using the same conditions as SLCO1B1. The single strand sequencing templates were purified using Pyromark ID instrument (Qiagen, Germany). The single-nucleotide polymorphism (SNP) was determined by pyrosequencing on a Pyromark Q96 ID platform (Qiagen, Germany) using the PyroMark Gold ® Q96 Reagents (Qiagen, Germany) with specific primers indicated in Table 1 following the manufacturer's instructions. The resulting polymorphisms were identified automatically by PyroMark ID software (Qiagen, Germany), and verified by manual analysis. The CYP2C9*3 polymorphism was determined by PCR-pyrosequencing using specific primers (Table 1) as previously described (Zhao et al., 2009 ). Three to five samples for each polymorphism were randomly selected and directly sequenced using Sanger chain-termination method to verify the accuracy of pyrosequencing method, and the results were completely in agreement with pyrosequencing (Wan et al., 2012a (Wan et al., & 2012b . 
Subjects and pharmacokinetic study design
A total of 62 healthy Chinese men of Han ethnicity, between ages 18-24, were recruited for the pharmacokinetic study. These subjects had a BMI ranging from 18 to 24 and they were considered healthy as ascertained by physical examination. All subjects were non-smokers, were free of drugs, and abstained from coffee, tea and alcohol for at least 1 week before participating in the study.
These subjects were divided into six groups according to the ABCG2 c.[34G>A(;)421C>A] haplotypes as indicated in Tables 2 and 3. All subjects have a SLCO1B1 c.521TT genotype and a CYP2C9 wild type. After an overnight fast, they received a single oral dose of 10 mg rosuvastatin calcium tablet (AstraZeneca, Wuxi, Jiangsu, China) taken with 200 ml of water.
Meals were allowed 6 hours later after rosuvastatin administration. Venous blood was collected before rosuvastatin administration and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 
Statistical analysis
Pharmacokinetic data is expressed as mean ± SD in Table 3 and mean ± SEM in Figures.
Genetic equilibrium was tested according to Hardy-Weinberg formula using the chi-squared test.
Statistical analysis of pharmacokinetic data was carried out using SPSS version 14.0 (SPSS Inc., Chicago, IL). Differences among multiple groups were analyzed by one-way analysis of variance The frequency of the SLCO1B1 c.521T>C SNP was also determined in this population, and the frequencies of 521TT, 521TC and 521CC genotype were 80%, 19% and 1%, respectively, which was in Hardy-Weinberg equilibrium (χ 2 = 0.095, p=0.758).
Effect of ABCG2 421C>A and 34G>A polymorphisms on rosuvastatin pharmacokinetics
Sixty-two subjects selected from 800 healthy Chinese volunteers participated in the study of Considering the c.421C>A SNP in subjects with an ABCG2 c.34GG homozygotes, subjects that were c.421AA homozygotes had a 227% and 200% higher mean C max of rosuvastatin than those with c.421CC and c.421CA genotypes (p<0.001) as shown in Table 3 and Figure 1 . The mean AUC (0-∞) of rosuvastatin was 164% and 154% greater and the mean AUC (0-48h) was 164%
and 155% greater in the c.421AA homozygotes than those with the c.421CC and c.421CA
genotypes (p<0.001). In contrast, the mean CL/F value in c.421AA homozygotes was 63% and 64% lower (p<0.001) than those in subjects with c.421CC and c.421CA genotypes (Table 3) .
However, there were no statistically significant differences in AUC (0-∞) , AUC (0-48h) , and C max between c.421CC homozygotes and c.421CA heterozygotes or in T 1/2 and T max of rosuvastatin among the six studied haplotypes (Table 3) .
Like the c.421C>A SNP, the c.34G>A SNP in the c.421CC homozygous background also had a significant influence on rosuvastatin pharmacokinetics as shown in Table 3 and Figure 2 .
Subjects with the c.34AA genotype had a significant higher C max , AUC (0-∞) and AUC (0-48h) with a lower CL/F than those with the c.34GG and c.34GA genotypes (p<0.01). However, the alteration in rosuvastatin pharmacokinetics in subjects with c.34AA homozygote was significantly less compared to those with c.421AA homozygotes (see Table 3 and Figure 3 ). The AUC 0-∞ , AUC 0-48h and C max of rosuvastatin was 64%, 64% and 57% greater, while the CL/F was 44% lower in This article has not been copyedited and formatted. The final version may differ from this version. Figure   3 ). However, there were no statistically significant differences in T 1/2 and T max between these two groups.
This article has not been copyedited and formatted. The final version may differ from this version. homozygotes (see Table 3 ), similar to previous reports (Zhang et al., 2006; Keskitalo et al., 2009a; Lee et al., 2013) . Moreover, in c.34AA homozygotes, the plasma C max and AUCs of rosuvastatin were significantly higher than those with c.34GG homozygotes, indicating that the c.34G>A variant also plays a significant role in rosuvastatin pharmacokinetics. Recently, Kim et al (Kim et al., 2015) have reported that the ABCG2 c.421C>A variant significantly influenced the pharmacokinetics of bicalutamide in a gene dose-dependent manner, but c.34G>A did not have such an effect in healthy Korean male subjects. It is unclear whether the lack of change in bicalutamide pharmacokinetics in subjects with c.34AA genotype is due to the small sample size of the study or a drug specific action of ABCG2 genetic variants. The reason remains to be elucidated.
Most importantly, we demonstrated in the present study that the ABCG2 c.34G>A and c.421C>A compound heterozygotes, but not the heterozygotes of either c.34GA or c.421CA, had a significant impact on rosuvastatin disposition resulting in elevated plasma C max and AUCs (see Table 3 ). This demonstration in compound heterozygotes may explain, at least in part, the This article has not been copyedited and formatted. The final version may differ from this version. (Zhang et al., 2006) and Lee et al (Lee et al., 2013 ) reported significant differences in plasma C max and AUCs of rosuvastatin in the c.421CA heterozygotes when compared to c.421CC
homozygotes of healthy Chinese males. These changes were not observed in the c.421CA
heterozygous Caucasians (Keskitalo et al., 2009a ). This discrepancy is most likely due to the high frequency of compound heterozygotes in Chinese populations, accounting for over 55% of c.421CA heterozygotes (see Table 2 ). In contrast, both the c. , 2008; Morisaki et al., 2005) . On the other hand, the ABCG2 c.34AA variant has been shown to possess decreased efflux activity due to disturbed protein membrane localization, which could also result in increased drug absorption in the gastrointestinal track and drug accumulation in systemic circulation (Mizuarai et al., 2004) .
However, the molecular mechanism of how the compound c.34GA/421CA heterozygote affects rosuvastatin pharmacokinetics remains to be investigated.
The disposition of rosuvastatin may also be influenced by other genetic variations in addition to ABCG2 variants. It has been shown that the SLCO1B1 c.521T>C variant was able to alter rosuvastatin disposition in humans (Bolego et al., 2002; Pasanen et al., 2007) . To minimize the influence of SLCO1B1 c.521T>C in rosuvastatin pharmacokinetics, we genotyped the SLCO1B1 c.521T>C variant in subjects and only those subjects with SLCO1B1 c.521TT
genotype were included in the study. Furthermore, since approximately 10% of rosuvastatin is metabolized by CYP2C9 (Bolego et al., 2002) , we genotyped CYP2C9*3 in the volunteers and confirmed all 62 participants possessed CYP2C9 wild-type genotype (data not shown). Although it has been shown that rosuvastatin is a substrate of ABCB1 and ABCC2 transporters, pharmacokinetic analysis indicates that the genetic variations of ABCB1 and ABCC2 had no significant impact on rosuvastatin disposition in humans (Keskitalo et al., 2009b; Kitamura et al., 2008) . Taken together, this data suggests that the observed variation in rosuvastatin disposition is mainly due to genetic variants of the ABCG2 gene.
Finally, to the best of our knowledge, the present study is the largest study of the frequency of ABCG2 c.34G>A and c.421C>A variants in healthy Asian males with a sample size of 800. In agreement with previous studies (Kim et al., 2010) , we confirmed that the Chinese population, like other Asian populations, has the highest incidence of ABCG2 c.34G>A and c.421C>A
variants with a allele A frequency of 0.275 and 0.282, respectively (see Table 2 ), compared to a frequency of 0.175 and 0.103, and 0.10 and 0.023 in Caucasian and African-American populations (Kim et al., 2010) . It is obvious that this high allele frequency is an important factor to be considered in the administration of rosuvastatin in Asian populations. Additionally, a deviation of the Hardy-Weinberg equilibrium for the c.34G>A, but not c.421C>A variant was observed in this population. Although disequilibrium may arise from inbreeding, we are not aware of any consanguinity within the population as we recruited the subjects from a large urban area. As previously suggested, a deviation could be a consequence of the recruiting strategy despite the fact that the other tested polymorphism did not deviate from Hardy-Weinberg equilibrium (Kim et al., 2010; Böger et al., 2005; Böger et al., 2007) . A potential explanation is a sampling bias since all subjects were male. Further study is necessary to confirm this hypothesis.
Conclusion
We have demonstrated that both ABCG2 c. 
